Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Menin inhibitors in AML: providing options for patients with NPM1 mutation and KMT2A rearrangement

Eunice Wang • 9 Jun 2023
EHA 2023
Acute Myeloid Leukemia Leukemia

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, briefly discusses the rationale behind using menin inhibitors to treat patients with acute myeloid leukemia (AML), highlighting the important role of these agents in patients with NPM1 mutation and KMT2A rearrangement. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Eunice Wang

Managing FLT3-ITD mutant AML in remission
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
6:18
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
Eunice Wang et al. • 18 Sep 2026
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perl et al. • 20 Sep 2026
KOMET-007: ziftomenib in combination with venetoclax and azacitidine in R/R AML
1:59
KOMET-007: ziftomenib in combination with venetoclax and azacitidine in R/R AML
Eunice Wang • 5 Dec 2025

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals